Eli Lilly's Taltz-Zepbound combination achieved significant improvements in two Phase 3b trials for plaque psoriasis and psoriatic arthritis with obesity. Combo therapy led to complete skin clearance and weight loss in psoriasis, and rapid disease activity reduction in psoriatic arthritis. The results were presented at AAD 2026.
FDA approved Medtronic's Hugo for urologic procedures; a new robotic and AR system showed high precision in jaw surgery; East and Central Africa saw its first robotic-assisted knee replacements.
Two new studies advance Lyme disease research: anti-lipid antibodies may enable earlier diagnosis and detect persistent symptoms, while cell wall changes in Borrelia burgdorferi offer insights into Lyme arthritis pathogenesis and potential treatment targets.
Australia's Medical Research Future Fund is investing billions across multiple health research areas, including $100 million for arthritis research over 10 years, AU$22.9 million for dementia projects, and $436 million in 209 grants for Indigenous health research since 2017.
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Analysis shows around a third of 54 drugs on TrumpRx.gov are cheaper in the UK, while the platform offers significant savings primarily for obesity and fertility drugs not typically covered by insurance.
New research reveals semaglutide may directly repair cartilage in osteoarthritis patients, while a separate study raises concerns about SNAC, an ingredient used in oral semaglutide formulations, and its effects on gut health.
Vie Ventures, a life sciences venture capital firm focused on autoimmune and immune-mediated diseases, announced that Jeff Bluestone, PhD, has been named Managing Director, joining founders Steven St. Peter, MD, and Luke Evnin, PhD.
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
Researchers from Stanford Medicine developed an injection that reprograms cells to regrow cartilage by blocking the protein 15-PGDH, offering potential treatment for osteoarthritis from aging or injury.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07775612 |
Pain-Sleep in Rheumatic Disease |
NOT_YET_RECRUITING | NA |
| NCT07767669 |
A Controlled Study to Evaluate the Effects of a Topical Cream on Symptoms of Arthritis, Joint, and Muscle Pain |
COMPLETED | NA |
| NCT07755085 |
GLP-1s in Hip and Knee Arthroplasty |
NOT_YET_RECRUITING | PHASE4 |
| NCT07580976 |
Tru-Vu Wrist Positioning Aid Multi-Center Implementation Within NLHS |
NOT_YET_RECRUITING | PHASE3 |
| NCT07515872 |
Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07478679 |
Radiation to Treat Joint Damage Caused by Cancer Immunotherapy |
NOT_YET_RECRUITING | PHASE1 |
| NCT07363876 |
The Efficacy of Ultrasonication in Combination With Corticosteroid Intraarticular Injection for Arthritis |
NOT_YET_RECRUITING | NA |
| NCT07284563 |
Ultralow Dose PET Imaging for 18F-NaF Uptake |
RECRUITING | PHASE2 |
| NCT07272850 |
Comparison Between JAK Inhibitors and Traditional Treatment of Rheumatoid Arthritis |
NOT_YET_RECRUITING | |
| NCT07151430 |
Development and Validation of a Comprehensive Management Service Package for Older Adults With Multimorbidity |
NOT_YET_RECRUITING | NA |
